← Cancer Research Communications
Papers in Cancer Research Communications
Page 6 · newest first
- Succinate dehydrogenase B (SDHB) overexpression with enzymatic dysfunction defines a distinct subtype of undifferentiated pleomorphic sarcomaCancer Research Communications · 2025
- Multiplexed imaging mass cytometry reveals tumor-immune microenvironment-dependent hormone receptor expression in adult type ovarian granulosa cell tumorsCancer Research Communications · 2025
- Development and Application of MiMouse, a Comprehensive Genomic Profiling Panel for Credentialing Mouse Tumor ModelsCancer Research Communications · 2025
- Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype StratificationCancer Research Communications · 2025
- Initial-Care Medical and Prescription Costs for Incident Metastatic versus Non-Metastatic Colorectal CancerCancer Research Communications · 2025
- Efficacy and safety of nivolumab monotherapy in patients with high PD-1 positive CD8/Treg ratio in advanced NSCLC and GC: A phase II, multicenter studyCancer Research Communications · 2025
- Genomic landscapes of endometrioid and mucinous ovarian cancers and morphologically similar tumor typesCancer Research Communications · 2025
- Auranofin synergizes with cisplatin in reducing tumor burden of Notch-dependent ovarian cancerCancer Research Communications · 2025
- The Non-Coding Mutational Landscape of Pancreatic Cancer Reveals Recurrent Somatic Mutations in Enhancer RegionsCancer Research Communications · 2025
- Functional analysis of rare RAS variants of unknown significanceCancer Research Communications · 2025
- A First-In-Human Dose-Escalation Phase 1 Study of Basroparib (STP1002), a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid TumorsCancer Research Communications · 2025
- RAS pathway inhibitors combined with targeted agents are active in patient-derived spheroids with oncogenic KRAS variants from multiple cancer typesCancer Research Communications · 2025
- Novel Afro-Caribbean Prostate Cancer Model Reveals ancestry-specific Drug Vulnerabilities with Therapeutic Implications for Black PatientsCancer Research Communications · 2025
- Pancreatic cells are resistant to KRAS(Q61L) expression due to hyperactive ERK/MAPK signaling and apoptosis inductionCancer Research Communications · 2025
- Immune activation signatures associated with fatigue in cancer patients undergoing immune checkpoint inhibitor therapyCancer Research Communications · 2025
- Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for OsteosarcomaCancer Research Communications · 2025
- SALL4 is required for YAP1-dependent malignant and regenerative hepatocyte-to-cholangiocyte reprogrammingCancer Research Communications · 2025
- IPH5201, an anti-CD39 monoclonal antibody, as monotherapy or in combination with durvalumab in advanced solid tumorsCancer Research Communications · 2025
- Prognostic impact of immune-related adverse events on combination immune checkpoint/tyrosine kinase inhibition for metastatic renal cancerCancer Research Communications · 2025
- Preclinical evaluation of folate receptor-alpha chimeric antigen receptor T cells (FOLR1-CART) exhibit highly efficient anti-tumor activity against osteosarcomaCancer Research Communications · 2025
- GPSai: A Clinically Validated AI Tool for Tissue of Origin Prediction During Routine Tumor ProfilingCancer Research Communications · 2025
- Prostate-Specific Antigen Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naive Prostate Cancer PatientsCancer Research Communications · 2025
- Gut microbiome profiling in Eµ-TCL1 mice reveals intestinal changes and a dysbiotic signature specific to chronic lymphocytic leukemiaCancer Research Communications · 2025
- Plasma proteomic analysis reveals complement system changes in irradiated female BALB/c mice during mammary carcinogenesisCancer Research Communications · 2025
- Mutational analysis of early, low-grade bowel polyps defines a subgroup with concurrent, high-risk oncogenic drivers independent of polyp sizeCancer Research Communications · 2025
- Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase 1 UnitCancer Research Communications · 2025
- Preclinical activity of Datopotamab deruxtecan (Dato-DXd), an antibody-drug conjugate targeting TROP2, in poorly differentiated endometrial carcinomasCancer Research Communications · 2025
- Response to anti-angiogenic therapy is associated with AIMP protein family expression in glioblastoma and lower-grade gliomasCancer Research Communications · 2025
- Seclidemstat (SP-2577) induces transcriptomic reprogramming and cytotoxicity in multiple fusion-positive sarcomasCancer Research Communications · 2025
- Inhibition of extracellular matrix protein fibulin-3 reduces immunosuppressive signaling and increases macrophage activation in glioblastomaCancer Research Communications · 2025
- Drug-drug interaction liabilities with BTK inhibitor TL-895Cancer Research Communications · 2025
- Impact of Staging, Histological Grading, and Racial Background on Lip Cancer Survival in the United States: Insights from the SEER Database (2010-2020)Cancer Research Communications · 2025
- Mesenchymal stem cells expressing CES1 and soluble TRAIL activate CPT-11 and induce apoptosis in lung cancer brain metastatic lesionsCancer Research Communications · 2025
- Minimal impact of COVID-19 on one-year mortality on U.S. cancer patients diagnosed early in the pandemicCancer Research Communications · 2025
- Clinical Validity of FoundationOne Liquid CDx for Detection of BRAF V600E in Colorectal CancerCancer Research Communications · 2025
- Novel pre-treatment autoantibodies correlate with enfortumab vedotin-related dermatologic events in patients with advanced urothelial cancerCancer Research Communications · 2025
- GALNT7 stratifies dMMR/MSI colorectal cancer into distinct molecular subsets associated with prognosis and PD-L1 expressionCancer Research Communications · 2025
- A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3-Expressing Relapsed or Refractory Solid TumorsCancer Research Communications · 2025
- Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted TherapiesCancer Research Communications · 2025
- Phase 2 Study of Zilovertamab Vedotin in Participants With Metastatic Solid TumorsCancer Research Communications · 2025
- Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective AnalysisCancer Research Communications · 2025
- Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer StudyCancer Research Communications · 2025
- Collagen XVII Promotes Pancreatic Ductal Adenocarcinoma Tumor Growth through Regulation of PIK3R5Cancer Research Communications · 2025
- Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC ModelsCancer Research Communications · 2025
- One-Carbon Metabolism Inhibition Depletes Purines and Results in Profound and Prolonged Ewing Sarcoma Growth SuppressionCancer Research Communications · 2025
- Treatment Outcomes Differ for Racial and Ethnic Minorities with Advanced-Stage Laryngeal Cancer: A Florida Cancer Data System AnalysisCancer Research Communications · 2025
- ClinVar Database Evolution and Impact on Potential Pathogenic Germline Variant Reporting from Tumor Comprehensive Genomic ProfilingCancer Research Communications · 2025
- Glycemic Control and Prostate Cancer Mortality Risk in Veterans with Type 2 Diabetes MellitusCancer Research Communications · 2025
- Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and BarriersCancer Research Communications · 2025
- Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer ImmunotherapyCancer Research Communications · 2025